TheraRadar
← Back
Data updated: Mar 29, 2026

GENMAB US, INC.

OncologyMetabolicGastroenterology
Biotech

GENMAB US, INC. is a biotechnology company focused on Oncology, Metabolic, Gastroenterology.

2023
Since
1
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

EPKINLY 2025-11-18
Efficacy
EPKINLY 2025-09-11
Labeling
EPKINLY 2024-06-26
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 98%
1 drugs Phase 3: 9 Phase 2: 7 Phase 1: 31
Metabolic 1%
0 drugs Phase 1: 1
Gastroenterology 1%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Oncology, Gastroenterology, Metabolic
Pfizer big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology
EMD SERONO INC biotech
Oncology, Metabolic, Gastroenterology